Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CETLUKAST
- Development stage
- Phase 4
- Lead developer
- Wellmed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**CETLUKAST** is a Wellmed branded fixed-dose oral tablet containing levocetirizine dihydrochloride 5 mg and montelukast 10 mg. Levocetirizine is a selective histamine H1-receptor antagonist, while montelukast is a selective cysteinyl leukotriene receptor 1 antagonist; together, these small molecules suppress histamine- and leukotriene-mediated allergic symptoms. Wellmed lists CETLUKAST as a marketed tablet product in 10 × 10 Alu-Alu packaging. ([wellmedpharma.com](https://www.wellmedpharma.com/product/cetlukast/))
- Brand names
- CETLUKAST
- Other names
- levocetirizine + montelukast
02
Targets
HRH1 (Histamine H1 Receptor)CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)
Beyond the preview
Go deeper on CETLUKAST.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CETLUKAST.